For acute coronary syndrome and percutaneous coronary intervention
2 ~ 8 ℃ save
For the peptide (integrilin) is a new kind of polypeptide platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist, which inhibit platelet aggregation in the common way to inhibit platelet aggregation and thrombosis. Compared with monoclonal antibody acyclovir sheet resistance, for the peptide due to a single conservative amino acid replacement replacement - lysine arginine, combination of GP Ⅱ b/Ⅲ a stronger, more directional and specificity. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome.
Platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist drugs has developed a lot, at present there are three kinds of international can be used for clinical preparations, acyclovir single resistance (abciximab), for the peptide (eptifibatide) and for class had (tirofiban).
Domestic on platelet glycoprotein GP Ⅱ b/Ⅲ a receptor antagonist, little experience, the use of available drugs are very limited, only one kind of drug that class had listed for hydrochloric acid, thus the development of new platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist is imperative. The domestically produced ethabapeptides are imitations produced by chengdu suno biological products co., LTD.
For acute coronary syndrome and percutaneous coronary intervention.